Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

Craig L. Slingluff, Karl D. Lewis, Robert Andtbacka, John Hyngstrom, Mohammed Milhem, Svetomir N. Markovic, Tawnya Bowles, Omid Hamid, Leonel Hernandez-Aya, Joel Claveau, Sekwon Jang, Prejesh Philips, Shernan G. Holtan, Montaser F. Shaheen, Brendan Curti, William Schmidt, Marcus O. Butler, Juan Paramo, Jose Lutzky, Arvinda PadmanabhanSajeve Thomas, Daniel Milton, Andrew Pecora, Takami Sato, Eddy Hsueh, Suprith Badarinath, John Keech, Sujith Kalmadi, Pallavi Kumar, Robert Weber, Edward Levine, Adam Berger, Anna Bar, J. Thaddeus Beck, Jeffrey B. Travers, Catalin Mihalcioiu, Brian Gastman, Peter Beitsch, Suthee Rapisuwon, John Glaspy, Edward C. McCarron, Vinay Gupta, Deepti Behl, Brent Blumenstein, Joanna J. Peterkin

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence'. Together they form a unique fingerprint.

Medicine & Life Sciences